logo
HP 14″ Chromebook Drops Below AirPods Pro Pricing, 4.5-Star Intel Laptop With 4GB RAM and 64GB Storage

HP 14″ Chromebook Drops Below AirPods Pro Pricing, 4.5-Star Intel Laptop With 4GB RAM and 64GB Storage

Gizmodoa day ago
Chromebooks shine when you need reliable tools for school, light work, and streaming but do not want the weight or upkeep of a full Windows laptop. The HP 14″ Chromebook with an Intel Celeron processor leans into that promise. It boots in seconds, runs quietly, and slips into a backpack with room to spare for headphones and notebooks. If your to do list lives in Google Docs and your free time involves YouTube or cloud gaming, this compact computer keeps pace without fuss.
Head over to Best Buy to get the HP 14″ Chromebook for just $130, down from its usual price of $330. That is a discount of $200 and 61% off.
See at Best Buy
Open the lid and a 14 inch high definition display greets you with crisp text and bright colors, useful for both lecture notes and late night shows. Narrow side bezels trim extra plastic, so the footprint stays closer to a 13 inch laptop while still giving eyes a comfortable amount of space. The modern grey finish looks tidy on a classroom desk or kitchen counter and resists smudges when you adjust the angle.
ChromeOS is the star under the hood. The lightweight system pairs an Intel Celeron processor with 4 gigabytes of memory to handle dozens of browser tabs, video calls, and music streams at once without the sluggish feel older machines develop. A speedy 64 gigabyte eMMC drive keeps boot time short and auto updates install quietly in the background, so you spend more time working and less time waiting. Offline storage is easy to expand with a microSD card if you want extra room for downloads.
Typing feels familiar thanks to a full sized keyboard with evenly spaced keys, helpful for essays and emails that stretch past a few sentences. The roomy touchpad supports multitouch gestures, making it simple to swipe through long web pages or pinch to zoom on diagrams. A 720p webcam and dual microphones handle virtual classes and group chats, and a privacy switch lets you disable the camera when the meeting ends.
Ports cover daily needs. Two USB C slots handle charging and fast data, while two USB A ports wait for flash drives and a wired mouse. A headphone jack sits on the side for quiet study sessions. Wi Fi 6 keeps the signal steady on busy networks, and Bluetooth pairs wireless earbuds in seconds. Battery life often reaches through a school day, and a quick top up during lunch brings the gauge back into a comfort zone for evening streaming.
The HP 14″ Chromebook is still available for $130 at Best Buy, a significant drop from the regular $330 price and an easy upgrade for anyone ready to simplify work and play on the go.
See at Best Buy
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nutrien Declares Quarterly Dividend of US$0.545 per Share
Nutrien Declares Quarterly Dividend of US$0.545 per Share

Yahoo

time15 minutes ago

  • Yahoo

Nutrien Declares Quarterly Dividend of US$0.545 per Share

SASKATOON, Saskatchewan, August 06, 2025--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) announced today that its Board of Directors has declared a quarterly dividend of US$0.545 per share payable on October 17, 2025, to shareholders of record on September 29, 2025. Registered shareholders who are residents of Canada as reflected in Nutrien's shareholders register, as well as beneficial holders (i.e., shareholders who hold their common shares through a broker or other intermediary) whose intermediary is a participant in CDS Clearing and Depositary Services Inc. or its nominee, CDS & Co., will receive their dividend in Canadian dollars, calculated based on the Bank of Canada daily average exchange rate on September 29, 2025. Registered shareholders resident outside of Canada as reflected in Nutrien's shareholders register, including the United States, as well as beneficial holders whose intermediary is a participant in The Depository Trust Company or its nominee, Cede & Co., will receive their dividend in US dollars. However, registered shareholders of Nutrien may elect to change the currency of their dividend payments to US dollars or Canadian dollars, as applicable. In addition, Nutrien offers registered shareholders direct deposit by electronic funds transfer for dividend payments. Registered shareholders may elect to change the currency of their dividend and enroll for direct deposit by contacting, Nutrien's registrar and transfer agent, Computershare Investor Services Inc., directly (1-800-564-6253 or service@ Beneficial shareholders should contact their broker or other intermediary to determine the ability and necessary steps involved in an election to change the currency of their dividend payment. For further details, please visit All dividends paid by Nutrien are, pursuant to subsection 89(14) of the Income Tax Act (Canada), designated as eligible dividends. About Nutrien Nutrien is a leading global provider of crop inputs and services. We operate a world-class network of production, distribution and ag retail facilities that positions us to efficiently serve the needs of growers. We focus on creating long-term value by prioritizing investments that strengthen the advantages of our business across the ag value chain and by maintaining access to the resources and the relationships with stakeholders needed to achieve our goals. View source version on Contacts Jeff HolzmanSenior Vice President, Investor Relations and FP&A(306) 933-8545Contact us at: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Firefly Aerospace to price US IPO as it sets sights on a positive liftoff
Firefly Aerospace to price US IPO as it sets sights on a positive liftoff

Yahoo

time15 minutes ago

  • Yahoo

Firefly Aerospace to price US IPO as it sets sights on a positive liftoff

By Pritam Biswas and Arasu Kannagi Basil (Reuters) -Northrop Grumman-backed Firefly Aerospace, the buzzy space technology startup that put a lander on the moon, is set to price its U.S. IPO later on Wednesday. In a nascent but rapidly growing commercial space industry, Firefly's IPO has attracted investor attention because it successfully landed its uncrewed Blue Ghost spacecraft on the moon in its first attempt in March. Cedar Park, Texas-based Firefly Aerospace is set to sell 16.2 million shares of its stock, priced between $41 and $43 apiece. This range was raised earlier this week, signaling strong demand. U.S. President Donald Trump's focus on commercializing space technology and safeguarding the national interests in space has attracted venture capital firms and billionaires. Elon Musk's SpaceX — the most valuable private company in the world — has become a critical part of the U.S. satellite network, even prompting a need across the government to look for more contractors. The U.S. government is betting that diversifying its contractor base will foster innovation and cut the huge costs of sending rockets to space, as well as reduce over-reliance on a single provider for critical missions. NASA's procurement process now includes new entrants such as Firefly Aerospace and Sierra Space, alongside legacy companies, leveraging commercial partnerships for lunar landers, space station modules and cargo deliveries. While space-related IPOs have been scarce in recent years, the tide is starting to turn in 2025. Firefly's listing comes on the heels of the successful New York flotations of space and defense firms Karman, AIRO Group and Voyager. As of Tuesday's close, shares of Karman have more than doubled from their offer price, while Voyager has gained 10%. "Given Firefly and the success of Voyager, I think you are going to see several more space-related companies test the waters of a public offering," said Ross Carmel, partner at law firm Sichenzia Ross Ference Carmel. TO THE MOON Formed in 2017, Firefly designs and manufactures small- to medium-lift launch vehicles, lunar landers and orbital vehicles. It had a backlog of roughly $1.1 billion and over 30 planned launches under contract as of March 31. While Houston-based Intuitive Machines' Odysseus lander was the first private lander to reach the moon last year, it made a lopsided touchdown, landing mostly intact but dooming many of its onboard instruments. Firefly's was the second, but its Blue Ghost spacecraft landed safely, reaching the moon's surface a month and a half after launching atop a SpaceX rocket from NASA's Kennedy Space Center in Florida. Last month, Firefly secured a $176.7 million contract to deliver five NASA payloads to the Moon's South Pole in 2029. Firefly was valued at more than $2 billion in a 2024 funding round. The company's backers include aerospace-focused private investment firm AE Industrial Partners. U.S. defense contractor Northrop Grumman, which invested $50 million into Firefly to aid the production of their jointly developed rocket, is one of three suppliers of solid rocket motors (SRMs) to the United States. Firefly is expected to begin trading on the Nasdaq under the ticker symbol "FLY" on Thursday.

Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies
Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies

Yahoo

time15 minutes ago

  • Yahoo

Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies

Novo Nordisk (NOVO, Financials) expanded its U.S. legal campaign against makers of unapproved versions of semaglutide the active ingredient in its blockbuster weight?loss and diabetes drugs Wegovy and Ozempic. The Danish drugmaker said Tuesday it filed 14 new lawsuits; the targets include telehealth providers, compounding pharmacies, and medical spas accused of selling compounded semaglutide under the fake guise of personalization. Warning! GuruFocus has detected 1 Warning Sign with NVO. The suits name firms such as Prism Aesthetics, Mochi Health, and Fella Health; some have also appeared in Eli Lilly's (LLY, Financials) litigation over knockoff versions of its weight?loss drug Zepbound. Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in some cases, the products allegedly contain illicit foreign?sourced active pharmaceutical ingredients. Compounders were temporarily allowed to produce semaglutide during a declared shortage; when the U.S. Food and Drug Administration ended that allowance, some companies shifted to offering personalized versions outside the approved drug label. Novo argues the approach violates state laws on corporate practice of medicine; it also raises safety concerns, as the copies have not been proven effective. Industry groups pushed back; Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said Novo's claims misrepresent the work of legitimate, state?licensed pharmacies. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store